Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study.

Anna Swenson¹, Waseem Ahmed², Jared Silver³, Shiyuan Zhang⁴, Amy Edgecomb⁵, Lingjiao Zhang⁶, Rafael Alfonso-Cristancho⁷, Richard Gliklich^1,8

¹OM1, Inc. Boston, Boston, MA, USA.

²Global Data Generation, GSK, London, UK.

³US Medical Affairs - Respiratory, GSK, Durham, NC, USA.

⁴Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA.

⁵Anti-Infectives and Respiratory, US Real-World Evidence and Health Outcomes Research, GSK, Philadelphia, PA, USA.

⁶Biostatistics, GSK, Collegeville, PA, USA.

⁷Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA. ralfonso@uw.edu.

⁸Harvard Medical School, Boston, MA, USA.

PubMed DOI

Abstract

BACKGROUND: Real-world evidence on the effectiveness of mepolizumab at reducing healthcare resource utilization (HCRU) and clinical symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is limited. METHODS: This real-world study used linked electronic medical record and claims data from the OM1 Real-World Data Cloud of clinician networks in the US, including an ear, nose and…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.